抑制VEGFR-2的新型神衍生物:设计,合成,抗增殖,对接和分子动力学模拟
Hazem A Mahdy1, Hazem Elkady1, Mohammed S Taghour1
1Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt.
Future medicinal chemistry
|July 19, 2023
概括
一种新的神胺衍生物,化合物5b,通过抑制VEGFR-2表现出强大的抗癌活性. 这种化合物还调节免疫反应,并表现出有利的类似药物的特性,标记它为癌症治疗的有希望的候选人.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 癌症生物学 癌症生物学
背景情况:
- 血管内皮生长因子受体2 (VEGFR-2) 是癌症治疗的关键标.
- 衍生物为开发新型治疗剂提供了支架.
研究的目的:
- 设计和合成新的神衍生物.
- 评估这些衍生物作为癌症治疗中VEGFR-2的潜在抑制剂.
主要方法:
- 在体外抗增殖和VEGFR-2抑制测定.
- 在Silico分子对接和动力学模拟.
- 计算的ADMET (吸收,分布,新陈代谢,分泌和毒性) 研究.
主要成果:
- 化合物5b表现出显著的抗增殖和VEGFR-2抑制作用.
- 化合物5b表现出亡活性和调节的免疫标记物 (增加IL-2,减少TNF-α).
- 分子模拟证实了对VEGFR-2的强烈结合亲和力,ADMET研究预测了良好的类似药物的潜力.
结论:
- 化合物5b是一种有前途的抗癌剂,向VEGFR-2.
- 合成的铁胺衍生物需要进一步研究以进行临床开发.
相关概念视频
Structure-Activity Relationships and Drug Design
773
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
773
Drug Discovery: Overview
8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K


